Interferon-α therapy for chronic active Epstein-Barr virus infection: Potential effect on the development of T-lymphoproliferative disease

Yasunari Sakai, Shouichi Ohga, Yasuhiko Tonegawa, Hidetoshi Takada, Futoshi Nakao, Hideki Nakayama, Tomonobu Aoki, Shunji Yamamori, Toshiro Hara

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)

Abstract

Purpose: A patient with aggressive chronic active Epstein-Barr virus (CAEBV) infection is described whose disease activity subsided after interferon (IFN)-α therapy. Patient and Methods: The patient had intermittent fever, cytopenia, liver dysfunction, hepatosplenomegaly, abnormal titers of EBV-associated antibodies, and positive EBV genomes. Results: Despite repeated trials of the antiviral agents prednisolone and γ- globulin, his condition deteriorated. The administration of IFN-α (1 x 105 U/kg subcutaneously 3 times per week) led to a dramatic clinical improvement. During the IFN-α therapy, the rearrangement bands of T-cell antigen receptor genes disappeared assessed by Southern blotting with a decrease in the number of activated T cells, although the EBV-genome remained evident. Conclusions: These observations suggest that IFN-α is useful in managing CAEBV, possibly restraining the clonal development of T-lymphoproliferative disease (LPD) and EBV-associated B-LPD, although it does not eradicate the proliferation of EBV.

Original languageEnglish
Pages (from-to)342-346
Number of pages5
JournalJournal of Pediatric Hematology/Oncology
Volume20
Issue number4
DOIs
Publication statusPublished - Jul 1 1998

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Interferon-α therapy for chronic active Epstein-Barr virus infection: Potential effect on the development of T-lymphoproliferative disease'. Together they form a unique fingerprint.

Cite this